Trial intelligence / Profile preview

Bimekizumab Self-Injection Device Study in Plaque Psoriasis

NCT03766685Phase 3Completed

Sponsor
UCB
Start
Dec 2018
Primary completion
Jul 2020
Modality
Recombinant Proteins and Enzymes, Monoclonal Antibodies
Countries
2
01

Overview

A Phase 3 trial of bimekizumab in psoriasis, sponsored by UCB. Started Dec 2018; status: completed.

02

Drugs

bimekizumab
03

Conditions

psoriasis

Beyond the preview

Go deeper on NCT03766685.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03766685.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call